Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

X Stop follow-up data

This article was originally published in The Gray Sheet

Executive Summary

Four-year follow-up data published in the July issue of Journal of Spinal Disorders & Techniques suggest that lumbar spinal stenosis patients treated with X Stop have "significantly greater improvement," according to St. Francis Medical. Moreover, 78% of the 18 patients had successful long-term outcomes. The results follow a separate study recently published in the Journal of Neurosurgery: Spine demonstrating that X Stop had a significantly greater clinical success rate (63.4%) than nonoperative care (12.9%). A new technology add-on payment for FY '07 is pending additional data on substantial clinical improvement (1"The Gray Sheet" April 17, 2006, p. 5)...

You may also be interested in...



CMS Indecisive On New Add-On Payment Candidates

Medtronic's Restore rechargeable implantable neurostimulator would continue to get federal add-on payments but its older Kinetra neurostimulator would not if CMS solidifies its proposed inpatient prospective payment rules for fiscal year 2007

Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States

Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023759

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel